*3.2. Prognostic Factors in Real-World Practice*

The clinical benefit of nivolumab, as shown in registration trials, applies to the entire patient population, but further analysis of the data suggests that some patients may benefit more than others. However, unfavorable responses to nivolumab treatment can be also observed. Therefore, it is important to identify additional prognostic factors that can be used in treatment decision-making. The real-world data are helpful in this regard.
